文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

亚特兰大队列中HIV与重症猴痘的关联

Associations Between HIV and Severe Mpox in an Atlanta Cohort.
PubMed 文献 · J Infect Dis · 2024-01-01

分析2022年6月1日至10月7日佐治亚州亚特兰大3个医疗系统395例猴痘确诊者的队列,其中324例(82.0%)为HIV感染者。多变量分析显示,HIV感染者发生重症猴痘的比值比为2.52(95%CI 1.01-6.27);HIV载量>200拷贝/mL者发生重症猴痘的比值比为2.10(95%CI 1.00-4.39)。

要点

  • 395例猴痘患者中324例(82.0%)为HIV感染者,77例(19.5%)发生重症猴痘,1例(0.3%)死亡。
  • HIV感染者重症猴痘比值比为2.52(95%CI 1.01-6.27),高于无HIV感染者。
  • HIV载量>200拷贝/mL者重症猴痘比值比为2.10(95%CI 1.00-4.39),高于病毒学抑制者。

核心结论

  • HIV载量未抑制的猴痘患者比无HIV感染者或病毒学抑制的HIV感染者出现更多猴痘并发症、住院和迁延病程。
  • 作者认为,确诊猴痘且HIV载量未抑制的HIV感染者值得特别积极的监测和治疗。

研究设计与样本

  • 研究为队列分析,纳入2022年6月1日至2022年10月7日在佐治亚州亚特兰大3个医疗系统确诊猴痘的395例个体。
  • 采用多变量logistic回归分析HIV状态与重症猴痘(按美国疾病控制与预防中心定义)的关联,并在HIV感染者中分析CD4+ T细胞计数和HIV载量与重症猴痘的关联。

主要发现

  • 395例猴痘确诊者中384例(97.2%)为顺性别男性,335例(84.8%)自认黑人,324例(82.0%)为HIV感染者。
  • 257例已知HIV载量的HIV感染者中90例(35.0%)HIV载量>200拷贝/mL。
  • 77例(19.5%)发生重症猴痘,1例(0.3%)死亡;112例(28.4%)被处方替考韦瑞特,其中包括56例(72.7%)重症猴痘患者。
  • 总人群多变量分析中,HIV感染者重症猴痘的比值比为2.52(95%CI 1.01-6.27),高于无HIV感染者。
  • HIV感染者多变量分析中,HIV载量>200拷贝/mL者重症猴痘的比值比为2.10(95%CI 1.00-4.39),高于病毒学抑制的HIV感染者;较低CD4+ T细胞计数与重症猴痘在单变量分析中呈显著关联,但在多变量分析中未发现显著关联。

关键数值与推荐

  • 重症猴痘按美国疾病控制与预防中心定义判定。
  • 总人群多变量分析:HIV感染者重症猴痘比值比2.52(95%CI 1.01-6.27)。
  • HIV感染者多变量分析:HIV载量>200拷贝/mL者重症猴痘比值比2.10(95%CI 1.00-4.39)。

临床怎么用

  • 作者建议对确诊猴痘且HIV载量未抑制的HIV感染者进行特别积极的监测和治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Southeastern United States, the 2022 mpox outbreak disproportionately impacted people who are black and people with HIV (PWH). METHODS: We analyzed a cohort of 395 individuals diagnosed with mpox across 3 health care systems in Atlanta, Georgia between 1 June 2022 and 7 October 2022. We present demographic and clinical characteristics and use multivariable logistic regression analyses to evaluate the association between HIV status and severe mpox (per the US Centers for Disease Control and Prevention definition) and, among PWH, the associations between CD4+ T-cell count and HIV load with severe mpox. RESULTS: Of 395 people diagnosed with mpox, 384 (97.2%) were cisgender men, 335 (84.8%) identified as black, and 324 (82.0%) were PWH. Of 257 PWH with a known HIV load, 90 (35.0%) had > 200 copies/mL. Severe mpox occurred in 77 (19.5%) individuals and there was 1 (0.3%) death. Tecovirimat was prescribed to 112 (28.4%) people, including 56 (72.7%) people with severe mpox. In the multivariable analysis of the total population, PWH had 2.52 times higher odds of severe mpox (95% confidence interval [CI], 1.01-6.27) compared with people without HIV. In the multivariable analysis of PWH, individuals with HIV load > 200 copies/mL had 2.10 (95% CI, 1.00-4.39) times higher odds of severe mpox than PWH who were virologically suppressed. Lower CD4+ T-cell count showed a significant univariate association with severe mpox but was not found to be significantly associated with severe mpox in multivariable analysis. CONCLUSIONS: PWH with nonsuppressed HIV loads had more mpox complications, hospitalizations, and protracted disease courses than people without HIV or PWH with suppressed viral loads. PWH with nonsuppressed HIV loads who are diagnosed with mpox warrant particularly aggressive monitoring and treatment.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Aldred B, Scott JY, Aldredge A, et al. Associations Between HIV and Severe Mpox in an Atlanta Cohort. J Infect Dis. 2024. PMID: 38001044. doi:10.1093/infdis/jiad505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。